Literature DB >> 18753632

PON1 multitasks to protect health.

Janice E Chambers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18753632      PMCID： PMC2529123          DOI： 10.1073/pnas.0807062105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  10 in total

Review 1.  Oxidized LDL and HDL: antagonists in atherothrombosis.

Authors:  A Mertens; P Holvoet
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

2.  Determination of paraoxonase (PON1) status requires more than genotyping.

Authors:  R J Richter; C E Furlong
Journal:  Pharmacogenetics       Date:  1999-12

3.  Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon.

Authors:  A L Pond; H W Chambers; C P Coyne; J E Chambers
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

4.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

Authors:  A D Watson; J A Berliner; S Y Hama; B N La Du; K F Faull; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux.

Authors:  Leonid Gaidukov; Mira Rosenblat; Michael Aviram; Dan S Tawfik
Journal:  J Lipid Res       Date:  2006-08-16       Impact factor: 5.922

6.  Effects of sarin on the nervous system of subway workers seven years after the Tokyo subway sarin attack.

Authors:  Koichi Miyaki; Yuji Nishiwaki; Kazuhiko Maekawa; Yasutaka Ogawa; Nozomu Asukai; Kimio Yoshimura; Norihito Etoh; Yukio Matsumoto; Yuriko Kikuchi; Nami Kumagai; Kazuyuki Omae
Journal:  J Occup Health       Date:  2005-07       Impact factor: 2.708

7.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin.

Authors:  H G Davies; R J Richter; M Keifer; C A Broomfield; J Sowalla; C E Furlong
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

8.  Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning.

Authors:  Richard C Stevens; Stephanie M Suzuki; Toby B Cole; Sarah S Park; Rebecca J Richter; Clement E Furlong
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-18       Impact factor: 11.205

Review 9.  Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism.

Authors:  Lucio G Costa; Toby B Cole; Gail P Jarvik; Clement E Furlong
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

10.  Increased influence of genetic variation on PON1 activity in neonates.

Authors:  Jia Chen; Madhu Kumar; Wendy Chan; Gertrud Berkowitz; James G Wetmur
Journal:  Environ Health Perspect       Date:  2003-08       Impact factor: 9.031
  10 in total
  6 in total

Review 1.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

2.  Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey.

Authors:  Man-huei Chang; Ajay Yesupriya; Renée M Ned; Patricia W Mueller; Nicole F Dowling
Journal:  BMC Med Genet       Date:  2010-04-20       Impact factor: 2.103

3.  Mechanistic Insights into the Hydrolysis of Organophosphorus Compounds by Paraoxonase-1: Exploring the Limits of Substrate Tolerance in a Promiscuous Enzyme.

Authors:  Sivaramakrishnan Muthukrishnan; Vivekanand S Shete; Toby T Sanan; Shubham Vyas; Shameema Oottikkal; Lauren M Porter; Thomas J Magliery; Christopher M Hadad
Journal:  J Phys Org Chem       Date:  2012-12       Impact factor: 2.391

Review 4.  Human paraoxonase 1 as a pharmacologic agent: limitations and perspectives.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  ScientificWorldJournal       Date:  2014-10-20

5.  Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders.

Authors:  Ignazio Stefano Piras; Stefano Gabriele; Laura Altieri; Federica Lombardi; Roberto Sacco; Carla Lintas; Barbara Manzi; Paolo Curatolo; Maria Nobile; Catia Rigoletto; Massimo Molteni; Antonio M Persico
Journal:  Antioxidants (Basel)       Date:  2021-01-22

6.  Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?

Authors:  Kimberly A Davis; J Allen Crow; Howard W Chambers; Edward C Meek; Janice E Chambers
Journal:  Environ Health Perspect       Date:  2009-03-12       Impact factor: 9.031
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.